MyFinsight
Home
Blog
About
Proceeds from exercise of
common stock options
$166K
(-45.39%↓ Y/Y)
Net cash provided by
financing activities
$166K
(-99.54%↓ Y/Y)
Net increase in cash
and cash...
-$21,197K
(-456.19%↓ Y/Y)
Canceled cashflow
$166K
Stock-based compensation
$2,609K
(4.07%↑ Y/Y)
Accrued and other
liabilities
$2,186K
(69.72%↑ Y/Y)
Loss from equity
method investment
-$709K
(23.60%↑ Y/Y)
Accretion related to
marketable securities
-$185K
(-129.60%↓ Y/Y)
Operating lease
right-of-use asset
-$92K
(44.24%↑ Y/Y)
Accounts receivable
-$37K
Depreciation and
amortization
$34K
(-33.33%↓ Y/Y)
Other assets
-$7K
(-16.67%↓ Y/Y)
Maturities of marketable
securities
$47,357K
(51.43%↑ Y/Y)
Net cash used in
operating activities
-$15,398K
(-9.67%↓ Y/Y)
Net cash used in
investing activities
-$5,965K
(62.85%↑ Y/Y)
Canceled cashflow
$5,859K
Canceled cashflow
$47,357K
Net (loss) income
-$17,959K
(-349.60%↓ Y/Y)
Purchases of marketable
securities
$47,740K
(1.18%↑ Y/Y)
Prepaid and other
current assets
$2,542K
(335.15%↑ Y/Y)
Accounts payable
-$650K
(-217.12%↓ Y/Y)
Operating lease liability
-$106K
(-171.79%↓ Y/Y)
Investment in angel
pharmaceuticals
$5,000K
Purchases of property and
equipment
$582K
(290.60%↑ Y/Y)
Back
Back
Cash Flow
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)
source: myfinsight.com